China National Pharmaceutical Group seeks to develop its own mRNA Covid vaccine

[ad_1]

Covid-19 vaccine update

Sinopharm is developing a self-produced messenger RNA inoculant for Covid-19, becoming one of the first large Chinese pharmaceutical groups to adopt this technology to combat the disease.

This state-owned pharmaceutical group’s move comes as people are increasingly concerned about the efficacy of traditional inactivated virus vaccines, which dominate the promotion in China. Some studies have shown that jabs produce fewer antibodies than mRNA injections.

Inactivated vaccines, such as the existing Sinopharm Coronavirus disease vaccine, Using dead virus particles to generate an immune response, and mRNA jabs contain genetic instructions to tell cells to make viral proteins to activate the immune system.

Sinopharm is not the only Chinese company developing its own mRNA vaccine. The smaller manufacturer Walvax Biotechnology is already conducting trials.

But large companies such as Sinopharm Group entered mRNA market Can greatly promote the development of this technology in China.

“They are working hard to develop these… next-generation vaccines, because the first-generation vaccines must be bolstered and may have to be injected regularly,” said Jin Dongyan, a virologist at the University of Hong Kong. “MRNA vaccines are much more effective than inactivated vaccines.”

The German pharmaceutical company BioNTech, which cooperates with distribution partners Pfizer and China Fosun Pharma to provide mRNA vaccines, has also targeted the Chinese market and is Waiting for formal approval Jab from Beijing.

Zhu Jingjin, party secretary of the China National Biotechnology Group, a subsidiary of Sinopharm, said that the company is developing an mRNA vaccine and a broad-spectrum recombinant protein vaccine that is undergoing clinical trials. Recombinant protein injection targets the spike protein used by viruses to enter and infect human cells.

“We have developed [the] Delta and Beta versions,” Zhu told Chinese official media at the China International Trade in Services Fair in Beijing. He added that the Phase I and Phase II clinical trials of recombinant protein injection have been completed.

China has already received more than 2 billion doses of vaccines, most of which are inactivated vaccines developed by Sinopharm and another private biotechnology group, Kronosing.

These vaccines can be stored at higher temperatures than mRNA vaccines, have been approved by the World Health Organization for emergency use, and have been shipped to more than 100 countries.

However, some countries are studying whether it is possible to improve the protection against serious infections by combining an inactivated virus vaccine with another more efficient vaccine (such as a vaccine using mRNA technology).

China National Pharmaceutical Group Vaccine Phase III Trial Shows 79% effective If the injections are given three weeks apart, they can fight the symptomatic Covid infection. The effective rate of BioNTech injection is 95%.

Cambodia stated that it will provide a third dose of Oxford/AstraZeneca vaccine, which is an adenovirus vector vaccine, to frontline staff who have received Sinopharm or Huaxing.

Walvax said in a stock exchange filing last week that it has received approval from the governments of Mexico and Indonesia to conduct phase 3 trials of its mRNA drug candidates. The lens is being jointly developed with the Suzhou Aiboyuan Biosciences Company in China and the Chinese Academy of Military Sciences.

[ad_2]

Source link